Views

Fundraising in Oncology Biotech: A Cynical Reflection for Optimistic Action
An article from January 2nd on Endpoints News titled, “A look at biotech's year of the megaround” reports that the biotech industry saw 96 nine-figure funding rounds in 2024. About one-third were preclinical and nearly the same amount for Phase 1. Most were Series A or B, with roughly one-third being oncology, in part or in entirety.
View Jan 23, 2025
Drill Down & Catch Up: The Role of Biomarkers in Neurodegenerative Disease
Lumanity offers extensive experience-based strategic guidance and insights in the field of neuroscience. Our goal is to provide our clients with actionable solutions that de-risk and optimize the development and commercialization of therapies, ultimately improving the lives of patients who are impacted across a range of conditions.
View Nov 4, 2024